Brain Metastasis Management Varies Among Oncologists
Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists.
Diagnosis & Disease Information
Rapid Rituximab Administration Safe for Primary CNS Lymphoma
Rapid administration of rituximab over 90 minutes was safe and feasible for patients with primary central nervous system (CNS) lymphoma.
Onartuzumab Does Not Improve Clinical Outcomes in Glioblastoma
Onartuzumab does not improve clinical outcomes for patients with glioblastoma when given with bevacizumab.
Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
Less Cognitive Deterioration With Radiosurgery Among Patients With Brain Metastases
Among patients with 1 to 3 brain metastases, use of stereotactic radiosurgery (SRS) may result in less cognitive deterioration at 3 months.
New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma
Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.
MATRix Regimen as New Standard for Primary CNS Lymphoma
The MATRix regimen may be the new standard chemoimmunotherapy for the treatment of central nervous system (CNS) lymphoma.
Methotrexate, TMZ, and Rituximab Followed by hWBRT Safe for Patients With CNS Lymphoma
Treatment of primary central nervous system lymphoma with methotrexate, TMZ, and rituximab, followed by hWBRT and subsequent TMZ was safe.
Rindopepimut May Help Patients With EGFRvIII-Positive Recurrent Glioblastoma
New data from a phase 2 study of rindopepimut in patients with EGFRvIII-positive recurrent GBM showed a marked benefit in terms of overall survival.
BRCA1 Gene Expression May be Biomarker for Survival in Glioblastoma Multiforme
BRCA1 protein expression may be an important predictive biomarker of overall survival in glioblastoma multiforme (GBM).
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...